Results 161 to 170 of about 44,419 (235)

Design and synthesis of RAD51-BRCA2 protein-protein interaction disruptors to trigger synthetic lethality with Olaparib in pancreatic cancer cells

Synthetic lethality (SL) is a phenotypic condition in which cells do not survive due to the combination of two genetic perturbations that, taken individually, do not induce cell death.
Laura Poppi, Stefania Girotto, Marinella Roberti, Federico Falchi, Greta Bagnolini, Viola Previtali, Andrea Cavalli, Giovanni Ferrandi   +7 more
core  

Opportunistic Screening of High-Risk Breast Cancer Variants in Hospital Biobank Setting. [PDF]

Cancer Epidemiol Biomarkers Prev
Pehrsson M, Jakkula E, Ala-Kulju K, Loukola A, Niemelä J, Löfman K, Anttonen AK, Meretoja T, Mattson J, Lappalainen M, Pöyhönen M, Carpén O.   +11 more
europepmc   +1 more source

Refining breast cancer risk estimation in carriers of pathogenic <i>BRCA2</i> variants. [PDF]

Transl Cancer Res
Conde DM, Sandoval RL.
europepmc   +1 more source

Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites. [PDF]

Cancer Cytopathol
Pighi C, Settanni G, Angelini M, Bortesi L, Viassolo V, Ceccaroni M, Bruni F, Gori S, Zannoni GF, Pesci A.   +9 more
europepmc   +1 more source

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51. [PDF]

Cell Death Dis
Xiao D, Yao J, Yang X, Xie Y, Zhou X, Li D, Peng M, Wang W, Zou H, Yang X.   +9 more
europepmc   +1 more source

Production of recombinant human BRCA2 encoded proteins in Ecoli

, 2016
Cataloged from PDF version of article.
openaire   +1 more source

Comprehensive evidence for the pathogenicity of the <i>BRCA2</i> c.7847C>T (p.Ser2616Phe) variant specific to the Japanese population. [PDF]

J Med Genet
Yamazawa K, Ueki A, Kuga A, Hinoi T, Niitsu H, Minatogawa M, Kawano J, Minami S, Okawa M, Takei J, Ichikawa M, Enokido K, Akimaru N, Torii M, Tsuyuki S, Iguchi C, Inoue T, Nakajima T, Watanabe N, Tanoshima M, Harada-Shoji N, Taruno K, Arai M, Murakami F, Ogawa M, Tamura K, Sugano K, Tanakaya K, Inoue S, Murakami H, Nakashima M, Makabe T, Kosaki K, Matsui A.   +33 more
europepmc   +1 more source

From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review. [PDF]

Biochem Biophys Rep
Georgy DM, Sedeek HN, Abaza NE, Eldeeb SEK, Khamis SM, Elgamil MR, Magar RW.   +6 more
europepmc   +1 more source

Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers. [PDF]

Fam Cancer
Laitman Y, Aharon K, Schloss T, Margolin L, Friedman E.   +4 more
europepmc   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source